Gilead's Q4 Earnings: What to Expect on Tuesday?
Generado por agente de IAMarcus Lee
lunes, 10 de febrero de 2025, 2:23 pm ET1 min de lectura
GILD--
Gilead Sciences (GILD) is set to report its fourth-quarter and full-year 2023 earnings on Tuesday, February 11, 2025. Investors and analysts are eagerly awaiting the results, as the biopharmaceutical company has been a key player in the global healthcare landscape. Here's what to expect when Gilead reports its Q4 earnings.
Revenue and Earnings Growth
Gilead's revenue and earnings growth have been driven by its strong HIV and Oncology franchises. In the fourth quarter of 2023, the company reported total revenue of $7.1 billion, a 4% decrease compared to the same period in 2022. However, excluding Veklury (remdesivir) sales, product sales increased due to higher demand for flagship HIV therapy Biktarvy and favorable pricing dynamics in HIV, as well as contributions from breast cancer drug Trodelvy and Cell Therapy.
For the full year 2023, Gilead's revenue was $27.12 billion, a decrease of 0.60% compared to the previous year's $27.28 billion. Earnings were $5.67 billion, an increase of 23.37% over the same period.
TOI--
Gilead Sciences (GILD) is set to report its fourth-quarter and full-year 2023 earnings on Tuesday, February 11, 2025. Investors and analysts are eagerly awaiting the results, as the biopharmaceutical company has been a key player in the global healthcare landscape. Here's what to expect when Gilead reports its Q4 earnings.
Revenue and Earnings Growth
Gilead's revenue and earnings growth have been driven by its strong HIV and Oncology franchises. In the fourth quarter of 2023, the company reported total revenue of $7.1 billion, a 4% decrease compared to the same period in 2022. However, excluding Veklury (remdesivir) sales, product sales increased due to higher demand for flagship HIV therapy Biktarvy and favorable pricing dynamics in HIV, as well as contributions from breast cancer drug Trodelvy and Cell Therapy.
For the full year 2023, Gilead's revenue was $27.12 billion, a decrease of 0.60% compared to the previous year's $27.28 billion. Earnings were $5.67 billion, an increase of 23.37% over the same period.
Divulgación editorial y transparencia de la IA: Ainvest News utiliza tecnología avanzada de Modelos de Lenguaje Largo (LLM) para sintetizar y analizar datos de mercado en tiempo real. Para garantizar los más altos estándares de integridad, cada artículo se somete a un riguroso proceso de verificación con participación humana.
Mientras la IA asiste en el procesamiento de datos y la redacción inicial, un miembro editorial profesional de Ainvest revisa, verifica y aprueba de forma independiente todo el contenido para garantizar su precisión y cumplimiento con los estándares editoriales de Ainvest Fintech Inc. Esta supervisión humana está diseñada para mitigar las alucinaciones de la IA y garantizar el contexto financiero.
Advertencia sobre inversiones: Este contenido se proporciona únicamente con fines informativos y no constituye asesoramiento profesional de inversión, legal o financiero. Los mercados conllevan riesgos inherentes. Se recomienda a los usuarios que realicen una investigación independiente o consulten a un asesor financiero certificado antes de tomar cualquier decisión. Ainvest Fintech Inc. se exime de toda responsabilidad por las acciones tomadas con base en esta información. ¿Encontró un error? Reportar un problema
Comentarios
Aún no hay comentarios